NCT06305351View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 7, 2023

Primary Completion Date

May 15, 2024

Study Completion Date

June 21, 2024

Conditions
ObesityType 2 Diabetes Mellitus (T2DM)
Interventions
DRUG

K-757 and K-833 QD

Both administered orally once daily

DRUG

K-757 and K-833 BID

Both administered orally twice daily

DRUG

Matching placebo to K-757 and K-833 QD

Both administered orally once daily

DRUG

Matching placebo to K-757 and K-833 BID

Both administered orally twice daily

Trial Locations (1)

33143

QPS Miami, Miami

Sponsors

Lead Sponsor

Kallyope Inc.
All Listed Sponsors
lead

Kallyope Inc.

INDUSTRY

NCT06305351 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter